In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.
IGBA Joins ICH and Welcomes the Positive Vote of the General AssemblyGeneva, Switzerland (June 15, 2016) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to accept the IGBA as an Assembly Member of the International Council for Harmonisation of Technical Requirements… Read More
Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines AgendaDubrovnik, 9 June 2016 – During the next two days, the key pharmaceutical industry leaders from the generic, biosimilar and value added medicines industries will meet in Dubrovnik to foster international partnership, cooperation and dialogue and discuss the most recent challenges… Read More
IGBA commentary on FDA’s Draft Guidance on Labeling for Biosimilar ProductsBrussels, June 3, 2016 – IGBA thanks the Agency’s for providing an opportunity to comment on the Agency’s Draft Guidance on Labeling for Biosimilar Products (Docket No. FDA-2016-D-0643-0001). IGBA’s position is aligned with the key comments of the Biosimilar Medicines Group,… Read More
IGBA welcomes Productivity Commission Draft Report in Australia and supports immediate Australian patent reformFriday May 27, 2016 – The International Generic and Biosimilar Medicines Association (IGBA) represents companies that are actively engaged in the global manufacturing and trading systems for medicines. Our membership includes the EGA (Europe), the CGPA (Canada), the GPhA (USA), the… Read More
IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposalThe International Generic and Biosimilar medicines Association (IGBA) welcomes the WHO’s continuous interest in the development of a global identification system for biological substances, as well as the decision to perform an impact study assessment of the voluntary Biological Qualifier… Read More